CE Case Study: Managing New Breakthrough Therapies Atopic Dermatitis Advances

Mar 10, 2022 at 10:09 pm by Staff


 
Education for the Managed Care and Payer Professional
 
 
Click Here to Begin

Certified For:

Nurses: up to .5 ANCC contact hours
Physicians: up to .5 AMA PRA Category 1 Credits
Pharmacists: up to .5 contact hours (0.5 CEU) of ACPE credit
UAN: JA4008162-9999-22-042-H01-P
Educational Objectives
  • Examine the pathophysiology, burden, signs and symptoms, and heterogeneity of atopic dermatitis (AD)
  • Assess the latest therapeutic developments for the treatment of AD
  • Identify optimal payer benefit management strategies that can contribute to appropriate access and utilization for AD
  • Employ timely referral and collaborative, multidisciplinary management of AD patients
Expert Faculty
John Fox, MD, MHA
Chief Boundary Spanner
Foxworthy Healthcare Consulting, PLLC
Adam Friedman, MD, FAAD
Professor and Chair of Dermatology; Associate Residency Program Director
Director of Translational Research; Director of Supportive Oncodermatology
Department of Dermatology
George Washington School of Medicine and Health Sciences
Edmund Pezalla, MD, MPH
CEO
Enlightenment Bioconsult, LLC
 

Jointly provided by

      

This activity is supported by independent educational grants from Incyte Corporation, Pfizer Inc., Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

https://www.impactedu.net/ADCase2/

Sections: Grand Rounds